Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (334)
Guidance programme
(
2 selected
)
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Apply filters
Showing 301 to 325 of 334
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
Technology appraisal guidance
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Technology appraisal guidance
TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Technology appraisal guidance
10 September 2025
Treatments for non-small-cell lung cancer [ID6234]
Technology appraisal guidance
TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891
Technology appraisal guidance
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Technology appraisal guidance
TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Technology appraisal guidance
TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]
Technology appraisal guidance
TBC
Ublituximab for treating relapsing multiple sclerosis [ID6350]
Technology appraisal guidance
TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Technology appraisal guidance
TBC
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]
Technology appraisal guidance
TBC
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
Technology appraisal guidance
TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372
Technology appraisal guidance
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
Technology appraisal guidance
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Technology appraisal guidance
TBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
Technology appraisal guidance
TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Technology appraisal guidance
TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]
Technology appraisal guidance
TBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
Technology appraisal guidance
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Technology appraisal guidance
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Technology appraisal guidance
TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407
Technology appraisal guidance
TBC
Previous page
1
…
11
12
Current page
13
14
Page
13
of
14
Next page
Results per page
10
25
50
All
Back to top